| P50 | author | Eric J Small | Q97531370 |
| P2093 | author name string | Matthew R Cooperberg | |
| | Peter R Carroll | |
| | Thomas A Hope | |
| | John Kurhanewicz | |
| | Jeffry P Simko | |
| | Clifford E Berkman | |
| | Kenneth Gao | |
| | Youngho Seo | |
| | Hao G Nguyen | |
| | Henry F VanBrocklin | |
| | Susan M Noworolski | |
| | Salma Jivan | |
| | Rahul Aggarwal | |
| | Kirsten L Greene | |
| | Joseph Blecha | |
| | Spencer C Behr | |
| | Robert R Flavell | |
| | Beatrice Langton-Webster | |
| | Natalie J Korn | |
| | Romelyn De Los Santos | |
| P2860 | cites work | Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy | Q56969116 |
| | Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer | Q62099349 |
| | PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact | Q62590715 |
| | The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations | Q69506970 |
| | Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging | Q69705027 |
| | [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study | Q88645082 |
| | Overview of prostate-specific membrane antigen | Q95814834 |
| | 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. | Q33821017 |
| | Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer | Q35938051 |
| | A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer | Q36219010 |
| | Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer | Q37091554 |
| | Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy | Q37214430 |
| | Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer | Q37350456 |
| | F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients | Q37662669 |
| | Limited evidence for the use of imaging to detect prostate cancer: a systematic review. | Q38233614 |
| | Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. | Q39710843 |
| | Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study | Q41700675 |
| | Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer | Q41905456 |
| | Practical aspects of prostate MRI: hardware and software considerations, protocols, and patient preparation | Q46567823 |
| | Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy | Q47107456 |
| | 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends | Q47269407 |
| | (68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. | Q47693515 |
| | 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour | Q48295687 |
| | Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding | Q50210696 |
| | Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges? | Q52983369 |
| | PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 910-916 | |
| P577 | publication date | 2018-11-21 | |
| P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
| P1476 | title | Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer | |
| P478 | volume | 60 | |